Skip to main content
77°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
42.90
+0.26 (+0.61%)
Streaming Delayed Price
Updated: 11:16 AM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
60
61
Next >
Large US Drug Makers Highlight Indian Market For Their Blockbuster Drugs Including For Weight Loss
February 28, 2024
Eli Lilly's CEO, David Ricks, outlines plans to launch the obesity drug Tirzepatide in India next year, presenting opportunities amid competition from Novo Nordisk. Bristol Myers Squibb expands its R&D...
Via
Benzinga
Bristol Myers Squibb to Participate in the TD Cowen 44th Annual Health Care Conference
February 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
February 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
3 Highly Rated Biotech Stocks to Buy for 300% Gains
February 26, 2024
Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings.
Via
InvestorPlace
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
February 22, 2024
Via
Benzinga
How Is The Market Feeling About Bristol-Myers Squibb?
February 21, 2024
Via
Benzinga
Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb
February 09, 2024
Via
Benzinga
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
February 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
February 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
Mental Health Mavericks: 3 Stocks Changing the Game
February 21, 2024
Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.
Via
InvestorPlace
The 3 Best Stocks Beginning Investors Can Buy: February 2024
February 21, 2024
Starting your investment journey? Navigate the market with confidence! Discover 3 stocks for beginning investors in this article.
Via
InvestorPlace
Got $5,000? These 3 Stocks Are Dirt Cheap Buys With Plenty of Upside
February 21, 2024
Shares of these companies are trading at sizable earnings discounts.
Via
The Motley Fool
Top Cannabis Appointments You Should Know About: Aurora's New CFO And Other Changes
February 20, 2024
Cannabis multi-state operator Cresco Labs kicked off February by announcing the promotion of Greg Butler to the position of president. Tom Shuman, a CPG sales and marketing veteran, agreed to serve as...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or...
February 20, 2024
From
Bristol Myers Squibb
Via
Business Wire
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
February 17, 2024
Patience will be rewarded with these stocks.
Via
The Motley Fool
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
February 15, 2024
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.
Via
InvestorPlace
Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
February 14, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC
February 14, 2024
From
Bristol Myers Squibb
Via
Business Wire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
February 14, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
February 14, 2024
From
Bristol Myers Squibb
Via
Business Wire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
February 14, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
February 14, 2024
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
A Look At Pharma ETFs After Q4 Earnings
February 12, 2024
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth.
Via
Talk Markets
Topics
ETFs
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)
February 12, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
7 Dividend Stocks to Buy at a 52-Week Low
February 12, 2024
Each of these dividend stocks has been down sharply in the last 12 months but has fundamental reasons that support a turnaround.
Via
InvestorPlace
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
February 12, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare
February 09, 2024
Via
Benzinga
7 Biotech Stocks Fighting America’s Deadliest Diseases
February 08, 2024
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.
Via
InvestorPlace
How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month
February 08, 2024
Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease.
Via
Investor's Business Daily
3 Blue-Chip Stocks to Buy at a 52-Week Low in February
February 07, 2024
Higher-for-longer interest rates and undervalued metrics make it a good time to look for blue-chip stocks at a low price.
Via
InvestorPlace
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
60
61
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.